Literature DB >> 32341635

Multiple Sclerosis Medications in the VHA: Delivering Specialty, High-Cost, Pharmacy Care in a National System.

Kathryn Tortorice1, Natasha Antonovich1.   

Abstract

INTRODUCTION/IMPORTANCE: Pharmacotherapy for multiple sclerosis has increased significantly since 1993 when the first disease modifying therapy was approved. The expansion of therapies has been accompanied with differences in adverse effect profiles, efficacy, and cost. The most recent therapies pose the challenge of balancing these issues while providing optimal care. OBSERVATIONS: Several measures such as generic conversion and standardization of therapies can be employed to control costs of therapy. The safety and efficacy of these agents can be monitored by implementation of criteria for use and/or medication utilization evaluations.
CONCLUSIONS: A formulary management system encompasses methodologies to evaluate the relevant clinical and medical literature and includes a systematic approach for selecting medications for different diseases, conditions, and patients. Formulary systems often contain prescribing guidelines and clinical recommendations that assist health care professionals with providing high quality, value-based care for patients.
Copyright © 2020 Frontline Medical Communications Inc., Parsippany, NJ, USA.

Entities:  

Year:  2020        PMID: 32341635      PMCID: PMC7182246     

Source DB:  PubMed          Journal:  Fed Pract        ISSN: 1078-4497


  25 in total

1.  Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis.

Authors:  Maja Eriksson; Oluf Andersen; Björn Runmarker
Journal:  Mult Scler       Date:  2003-06       Impact factor: 6.312

2.  PML in a patient with lymphocytopenia treated with dimethyl fumarate.

Authors:  Thorsten Rosenkranz; Mark Novas; Christoph Terborg
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

Review 3.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Authors:  Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2017-12-21       Impact factor: 44.182

4.  Stopping Disease-Modifying Therapy in Nonrelapsing Multiple Sclerosis: Experience from a Clinical Practice.

Authors:  Gary Birnbaum
Journal:  Int J MS Care       Date:  2017 Jan-Feb

5.  Dimethyl fumarate associated lymphopenia in clinical practice.

Authors:  Erin E Longbrake; Anne H Cross
Journal:  Mult Scler       Date:  2014-11-28       Impact factor: 6.312

6.  Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.

Authors:  Ilya Kister; Tim Spelman; Raed Alroughani; Jeannette Lechner-Scott; Pierre Duquette; Francois Grand'Maison; Mark Slee; Alessandra Lugaresi; Michael Barnett; Pierre Grammond; Gerardo Iuliano; Raymond Hupperts; Eugenio Pucci; Maria Trojano; Helmut Butzkueven
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-06-13       Impact factor: 10.154

7.  Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.

Authors:  Jeffrey Cohen; Anna Belova; Krzysztof Selmaj; Christian Wolf; Maria Pia Sormani; Janine Oberyé; Evelyn van den Tweel; Roel Mulder; Norbert Koper; Gerrit Voortman; Frederik Barkhof
Journal:  JAMA Neurol       Date:  2015-12       Impact factor: 18.302

8.  Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

Authors:  J William L Brown; Alasdair Coles; Dana Horakova; Eva Havrdova; Guillermo Izquierdo; Alexandre Prat; Marc Girard; Pierre Duquette; Maria Trojano; Alessandra Lugaresi; Roberto Bergamaschi; Pierre Grammond; Raed Alroughani; Raymond Hupperts; Pamela McCombe; Vincent Van Pesch; Patrizia Sola; Diana Ferraro; Francois Grand'Maison; Murat Terzi; Jeannette Lechner-Scott; Schlomo Flechter; Mark Slee; Vahid Shaygannejad; Eugenio Pucci; Franco Granella; Vilija Jokubaitis; Mark Willis; Claire Rice; Neil Scolding; Alastair Wilkins; Owen R Pearson; Tjalf Ziemssen; Michael Hutchinson; Katharine Harding; Joanne Jones; Christopher McGuigan; Helmut Butzkueven; Tomas Kalincik; Neil Robertson
Journal:  JAMA       Date:  2019-01-15       Impact factor: 56.272

9.  Defining the clinical course of multiple sclerosis: the 2013 revisions.

Authors:  Fred D Lublin; Stephen C Reingold; Jeffrey A Cohen; Gary R Cutter; Per Soelberg Sørensen; Alan J Thompson; Jerry S Wolinsky; Laura J Balcer; Brenda Banwell; Frederik Barkhof; Bruce Bebo; Peter A Calabresi; Michel Clanet; Giancarlo Comi; Robert J Fox; Mark S Freedman; Andrew D Goodman; Matilde Inglese; Ludwig Kappos; Bernd C Kieseier; John A Lincoln; Catherine Lubetzki; Aaron E Miller; Xavier Montalban; Paul W O'Connor; John Petkau; Carlo Pozzilli; Richard A Rudick; Maria Pia Sormani; Olaf Stüve; Emmanuelle Waubant; Chris H Polman
Journal:  Neurology       Date:  2014-05-28       Impact factor: 9.910

10.  Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.

Authors:  Ralf Gold; Douglas L Arnold; Amit Bar-Or; Michael Hutchinson; Ludwig Kappos; Eva Havrdova; David G MacManus; Tarek A Yousry; Carlo Pozzilli; Krysztof Selmaj; Marianne T Sweetser; Ray Zhang; Minhua Yang; James Potts; Mark Novas; David H Miller; Nuwan C Kurukulasuriya; Robert J Fox; Theodore J Phillips
Journal:  Mult Scler       Date:  2016-07-11       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.